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A bullous eruption in a patient with psoriasis was 
first described by Bloom in 1929 (as cited by Weber) 
(1). Since then there have been several reports of bul-
lous pemphigoid occurring during the treatment of 
psoriasis, especially after ultraviolet (UV) B exposure. 
Comorbidity of these two diseases without treatment 
has also been reported (2,3).
Psoriasis is one of the most common chronic in-
flammatory skin diseases. Its etiopathogenesis is un-
known, but nonspecific inflammatory processes and 
specific immunologic factors have been described. 
Autoimmune processes occurring within the epi-
dermis and immunologic responses to exogenous 
infectious agents are suspected as causes, but not 
confirmed. In contrast, bullous pemphigoid (BP) rep-
resents a distinct autoimmune disease in which base-
ment membrane zone (BMZ) molecules are most 
affected (4). BP is an autoimmune subepidermal bul-
lous disease with circulating autoantibodies against 
BP antigen 1 (230kDa) and BP antigen 2 (180kDa). 
Antigen 2 is a transmembrane glycoprotein located 
in the hemidesmosomes and is the major antigenic 
target in this disorder (5,6). The BP180 NC16a domain 
is considered to be the most immunogenic site (7).
The occurrence of BP in patients with psoriasis has 
occasionally been reported (8). Although the patho-
genetic mechanism of comorbidity of psoriasis vul-
garis and BP is unclear, a common immunogenetic 
mechanism might be involved (9). Most previously 
reported cases attributed the occurrence of BP in 
psoriasis to photochemotherapy and phototherapy 
(PUVA, UVA, UVB311nm), topical treatment with an-
thralin, tar, and as a result of systemic application of 
anti-TNF antibodies (10). The role of PUVA therapy in 
the development of BP remains unknown. George 
at al. suggested that such changes may trigger the 
development of antibodies which may later cross-re-
act with proteins, such as the BP antigen, causing a 
bullous eruption to appear. The possibility that PUVA 
induces the alteration of immunologic reactivity of T-
helper and T-suppressor cells, allowing the develop-
ment of autoantibodies against native proteins, has 
also been raised (6,11).
A 55-year-old woman was referred to our depart-
ment with a ten days history of bullous lesions, ero-
sions, and exacerbated plaque psoriasis. Psoriasis was 
diagnosed in 1994, and various systemic and topical 
therapies (in combination or as single treatment) 
Figure 1. Bullous lesions located on a psoriatic plaque 
of the upper limb.
Figure 2. Bullous lesion located on a psoriatic plaque 
and uninvolved skin of the lower limb.
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were prescribed, such as topical corticosteroids, cy-
closporine, and methotrexate. Three courses of PUVA 
therapy (cumulative dose 291 J/cm²) had been given 
several days before hospitalization. 
On examination, extensive psoriatic plaques, ves-
icles and tense blisters up to 3 cm in diameter, filled 
with clear fluid, located on both the normal skin and 
psoriatic lesions were observed all over the body. The 
highest intensity of bullous skin lesions was found in 
the upper limbs and lower limbs (Fig. 1 and 2). No le-
sions were observed on the face or on the mucous 
membranes.
Routine laboratory tests such as biochemical tests, 
complete blood count, and urinalysis were normal. 
Chest radiography and abdominal ultrasonography, 
tumor markers CEA, and AFP showed no abnormali-
ties.
Two biopsy specimens were taken from psoriatic 
and bullous lesions for histopathologic examination, 
and one biopsy was taken from a perilesional bullous 
area located on the right forearm for a direct immu-
nofluorescence test (DIF). Histopathologic examina-
tion revealed a subepidermal blister with eosinophils, 
fibrin, and neutrophils. Perivascular edema and lym-
phohistiocytic infiltration with eosinophils was ob-
served in upper dermis (Fig. 3). DIF test showed linear 
C3c deposits at the dermal-epidermal junction (Fig. 
4). C3c was present at both the epidermal and der-
mal sides of BMZ in salt-split skin examination (Fig. 5). 
Figure 4. Direct immunofluorescence (DIF) study of 
uninvolved skin showing linear deposits of C3c at the 
dermal-epidermal junction.
Figure 5. Salt-split skin test showing C3c deposits at 
the epidermal and dermal sides of the substrate.
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Indirect immunofluorescence study (IIF) was done us-
ing monkey esophagus substrate and demonstrated 
IgG antibasement membrane zone antibodies (Fig. 
6).
Enzyme-linked immunosorbent assay (ELISA) 
confirmed high titers of anti-BP180 (>200 E/ml) and 
anti-BP230 (140 E/ml) with negative results for anti-
envoplakin, anti-Dsg1, anti-Dsg3, and anti-Col7A an-
tibodies.
After BP was diagnosed, the patient received 
prednisolone orally at a dose of 50 mg daily (0.8 
mg/kg body weight). After 1 week, during skin con-
trol examination there were no new lesions, and the 
existing ones were reduced. Prednisolon was gradu-
Figure 3. Subepidermal blister with eosinophils, fi-
brin, and neutrophils. Perivascular edema and lym-
phohistiocytic infiltration with eosinophils present in 
upper dermis (hemalaun and eosin; x 400).
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ally reduced (10 mg every week) until the skin lesions 
disappeared completely. Residual psoriatic plaques 
were treated with 1% hydrocortisone ointment si-
multaneously.
Bullous pemphigoid is sometimes considered a 
marker of oncogenesis, but patients with BP are most-
ly elderly, with a high base rate of cancer incidence. In 
our patient additional studies did not confirm tumor 
presence. She also did not receive any drugs that can 
contribute to the development of the disease (mainly 
diuretics and antihypertensives). PUVA-therapy ap-
plied during psoriasis treatment was the most likely 
BP induction factor. Skin lesions as a result of possible 
UVA overdosage were excluded. Histopathology and 
immunofluorescence clearly showed that our patient 
suffered from BP. UV radiation was most obvious trig-
ger of bullous pemphigoid in our patients.
Comorbidity of the two diseases supports the 
hypothesis that autoimmunity has a partial role in 
the etiology of psoriasis. There have been several re-
ports about the coexistence of these two diseases. 
It has been reported that UV radiation and an irrita-
tion therapies used in the treatment of psoriasis may 
lead to bullous pemphigoid. In predisposed cases 
psoralen together with UVA therapy causes the de-
position of antibasement membrane zone antibodies 
through immunological alterations (2,3).
Exposure of psoriatic lesions to ultraviolet radia-
tion (UVR) likely triggered to production of BP au-
toantibodies as a result of BP antigen configuration 
changes or as a secondary phenomenon demonstrat-
ed that BP180kD and alpha-6 integrin interaction is 
not only mediated by the BP epitope but is necessary 
for hemidesmosome formation (12,13). One possibili-
ty is that UVR may alter BMZ antigenicity and produc-
tion of antibodies against the BMZ molecules (14).
UVR is known to induce or aggravate several au-
toimmune bullous diseases. The precise mechanism 
by which this radiation induces blistering is not well 
understood, but several possible mechanisms have 
been proposed. One is release or activation of bound 
antigen and/or the inducement of antibody fixation 
by UV radiation (15). This concept was proposed on 
the basis of in vitro studies using serum from a pa-
tient with BP in which UVB radiation generated by a 
hot quartz lamp and high-dose radiographs led to in-
creased binding of antibodies to the BMZ (15).
Other proposed mechanisms include the activa-
tion of intracellular signaling pathways after binding 
of antibodies and increased production of inflamma-
tory mediators such as interleukins (IL-1, IL-8), tumor 
necrosis factor-alpha (TNF-α), and granulocyte mac-
rophage colony-stimulating factor (GM-CSF) (16,17). 
However, no definite mechanism of action for UVR 
induced blistering has been proposed. It is well know 
that psoralen-UVA (PUVA) therapy can itself induce 
acral bullous lesions, which cannot be attributed to 
immunologic causes, therapy overdose, or excessive 
psoralen uptake. It is more likely that the blistering 
is induced by direct damage to the dermo-epidermal 
junctional caused by the combination of UVA radia-
tion and psoralen (15,18-20).
In treatment of psoriasis, we should avoid the use 
of systemic corticosteroids; the treatment of choice 
for comorbidity of psoriasis and BP is methotrex-
ate. Even if the observed anti-inflammatory effect is 
short-term, long-term side effects far outweigh the 
benefits. In our case, we decided to apply short oral 
course of systemic corticosteroids because of rapid 
exacerbation of BP lesions with only single psoriatic 
plaques. The clinical result was very satisfactory, and 
we did not observe psoriasis exacerbation after dis-
continuation of prednisolone therapy. Proper treat-
ment in such clinical cases should be decided indi-
vidually, taking into account history of the disease, 
clinical course of psoriasis, and existing concomitant 
diseases.
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